Previous close | 10,250.00 |
Open | 10,326.00 |
Bid | 10,492.00 x 0 |
Ask | 10,494.00 x 0 |
Day's range | 10,308.00 - 10,500.00 |
52-week range | 6,499.80 - 11,000.00 |
Volume | |
Avg. volume | 2,861,525 |
Market cap | 162.569B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -58.30 |
Earnings date | 29 Apr 2022 |
Forward dividend & yield | 2.10 (2.05%) |
Ex-dividend date | 24 Feb 2022 |
1y target est | 111.72 |
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2